Orion Corporation to Commercialise Pembrolizumab Biosimilar in Europe
Orion Corporation has entered into an agreement with Qilu Pharma Europe for the exclusive distribution, marketing, and sale of Qilu's IV pembrolizumab biosimilar in the European market. Qilu Pharma will supply the product and receive a profit share, along with development, regulatory, and sales milestones.